corporate_fare

Kymera Therapeutics Inc.

Address: 500 North Beacon Street Floor 4

Sponsor Overview

assignment

Specializations

Atopic Dermatitis

Clinical research in moderate to severe atopic dermatitis focuses on inflammatory skin disease, with interest in symptom control, skin barrier dysfunction, and immune-driven disease activity.

Chronic inflammatory skin disease
Immune-mediated dermatology
Pruritus and skin inflammation

The sponsor’s dermatology portfolio is centered on oral therapeutic approaches for patients with persistent disease burden.

Eosinophilic Asthma

Research in uncontrolled moderate to severe eosinophilic asthma addresses airway inflammation, asthma control, and the role of eosinophilic pathways in respiratory disease.

Severe asthma
Eosinophilic inflammation
Airway disease

These studies reflect a therapeutic interest in respiratory conditions with ongoing inflammatory activity and unmet treatment needs.

Immunology

The sponsor’s clinical activity is concentrated in immune-mediated diseases, with emphasis on pathways that influence both dermatologic and respiratory inflammation.

Inflammatory signaling
Immune regulation
Type 2 inflammation

This area links the sponsor’s work across skin and airway disorders within a shared immunologic framework.

Inflammatory Disease Therapeutics

Kymera Therapeutics Inc. is active in therapeutic development for chronic inflammatory diseases, with a focus on conditions that require long-term disease management.

Inflammation-driven disorders
Oral therapy
Targeted treatment approaches

The current trial landscape is concentrated in dermatology and pulmonology through immune-focused clinical programs.

Trial Name	Country	Status
A Phase 2b Dose-Ranging Study of Oral KT-621 in Adults with Uncontrolled Moderate to Severe Eosinophilic Asthma	Austria Belgium Germany Italy Poland Romania Slovakia Spain	Recruiting
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study With an Open-label Period Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Participants with Moderate to Severe Atopic Dermatitis	Czechia Germany Poland	Not Recruiting